The RD Department of Bukwang Pharmaceutical Co., Ltd. attended the Spring Symposium held by the Korean Academy of Asthma, Allergy and Clinical Immunology at Grand Hilton Hotel in Seoul. A booth for Azeptin, Bukwang’s key anti-histamine agent, was set up to promote the product.
Azeptin is a branded anti-histamine agent containing azelastine as the key therapeutic ingredient, developed by MEDA of Germany. Due to its rapid onset and long duration of efficacy, Azeptin provides all-day efficacy with the convenient twice-daily (BID, bis in die) dosing. In addition to being indicated for allergic rhinitis, rash and dermatitis, Azeptin was also approved for treatment of asthma thanks to its recognized anti-inflammatory effects. Azeptin is available in two formulations of tablet and nasal solution. The nasal solution is a spray-type formulation which delivers the drug directly to the nasal cavity, thereby maximizing the efficiency as well.
The Spring Symposium by the Academy was attended by many physicians and pharmaceutical companies, reflecting the recent trend of rapidly increasing number of allergy and asthma patients. The Academy celebrated its 44th anniversary since its inception on the 30th of November, 1972.